Project Grant R01HL176955
Award Date 9/24/25
Completion Date 8/31/26
Dollars Obligated $1.4M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
New York, USA
Similar Awards
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Federal Grant Program CFDA 93.837 - Cardiovascular Diseases Research, will support research to define cellular pathways that regulate lipid flux and elucidate their impact on cardiovascular disease. The $773,259 award, with a project period from December 2024 to November 2028, will enable the University of California, Los Angeles (UCLA) to: 1) Identify novel cholesterol-responsive proteins in the...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), supports the development of a lesion-targeted nanotherapeutic to address vascular smooth muscle cell (VSMC) dysfunction and mitigate neointimal hyperplasia (NIH), which is a significant issue arising from vascular damage during interventions. The project aims to integrate in vitro transcribed CARMN RNA (a long non-coding RNA critical...
- The National Heart Lung and Blood Institute (NHLBI), under CFDA 93.837 Cardiovascular Diseases Research program, awarded a $129,600 Project Grant to Weill Medical College of Cornell University. The grant, with an award date of Sep 5, 2025 and an ultimate completion date of Aug 31, 2027, supports research to elucidate the molecular mechanisms of macrophage foam cell formation in the development of atherosclerotic plaques. The research aims to investigate the role of cholesterol transport proteins...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is supporting research to investigate how gut microbe-derived lipids, specifically N-acyl amides, can signal through the host receptor GPR119 to impact inflammatory and metabolic pathways related to cardiometabolic diseases like obesity and atherosclerosis. The $743,302 award to the Cleveland Clinic Lerner College of Medicine of Case Western...
- This $109,812 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research on using extracellular vesicles derived from endothelial cells to potentially treat vascular disease in MELAS, a common mitochondrial disorder. The research aims to characterize the mitochondrial content and quality within these extracellular vesicles and assess their ability to ameliorate inflammatory effects in MELAS-affected endothelial cells....
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) is funding research at the University of Arizona to investigate whether and how the hepatocyte protein TMEM141 regulates lipoprotein metabolism and atherosclerosis. The $744,453 award, which runs from August 1, 2025 through May 31, 2029, will utilize genetically modified mouse models and state-of-the-art techniques to study the role of TMEM141 in lipid and lipoprotein...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) provides $787,267 to Yale University from January 1, 2025 to November 30, 2028 to conduct research aimed at determining whether genetic deletion of the DHCR24 enzyme in macrophages or hepatocytes can attenuate the progression of atherosclerosis. The project will exploit novel animal models and cutting-edge genomic and metabolomic technologies to evaluate the therapeutic...
- The federal Project Grant award for "NUTRIENT SENSING OF APOPTOTIC CELLS BY MACROPHAGES RESOLVES INFLAMMATION, DRIVES ATHEROSCLEROSIS REGRESSION, AND PROMOTES FEATURES OF PLAQUE INSTABILITY" was provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) for $659,441.00. The award supports research to define the mechanisms underlying the successive clearance of apoptotic cells by macrophages, with the goal of revealing new therapeutic...
- This $787,453 federal Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Brigham & Women's Hospital Inc. aims to develop a new lipid-lowering and anti-inflammatory siRNA therapy for more effective treatment of atherosclerotic cardiovascular disease (ASCVD). The project will leverage the researchers' recent discoveries on the biological roles of epsin endocytic adaptor proteins in regulating lipid metabolism and arterial...
- This $292,500 Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to identify novel microproteins associated with normal hematopoiesis and hematopoietic diseases. The project will leverage existing transcriptomic and translation data to produce a comprehensive catalog of microproteins expressed in different hematopoietic cell types. This inter-disciplinary research conducted by the Sanford Burnham Prebys Medical Discovery...